LOG IN
SIGN UP
MARKET
SYBX
SYBX
Synlogic
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.090
0.000
0.00%
Opening 11:14 05/27 EDT
OPEN
1.090
PREV CLOSE
1.090
HIGH
1.140
LOW
1.070
VOLUME
52.35K
TURNOVER
42.99K
52 WEEK HIGH
4.540
52 WEEK LOW
1.020
MARKET CAP
76.57M
P/E (TTM)
-1.0955
1D
5D
1M
3M
1Y
5Y
Synlogic gets EU drug regulator's positive opinion on orphan designation for SYNB1618
Synlogic (NASDAQ:SYBX) on Tuesday said the European Union's drug regulator had given a positive opinion on the clinical-stage biotech's application for orphan designation for its phenylketonuria treatment SYNB1618. The European
Seekingalpha · 3d ago
BRIEF-Synlogic Receives Positive Opinion On Orphan Designation From European Medicines Agency For SYNB1618 For Treatment Of Phenylketonuria
reuters.com · 3d ago
Synlogic Announced Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that the European Medicines Agency (EMA) issued a pos...
Benzinga · 3d ago
Synlogic's Phenylketonuria Drug Candidate Receives Positive Opinion on Orphan Designation From European Medicines Agency
MT Newswires · 3d ago
Chardan Research Trims Synlogic's Price Target to $9 From $10, Citing Commercialization Timelines; Buy Rating Kept
MT Newswires · 05/13 04:54
Synlogic (NASDAQ:SYBX shareholders incur further losses as stock declines 28% this week, taking three-year losses to 85%
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...
Simply Wall St. · 05/12 14:51
Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 51.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 12:35
Recap: Synlogic Q1 Earnings
Synlogic (NASDAQ:SYBX) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/12 11:24
No Data
Learn about the latest financial forecast of SYBX. Analyze the recent business situations of Synlogic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 5 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
60.00%Strong Buy
40.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SYBX stock price target is 7.60 with a high estimate of 9.00 and a low estimate of 6.00.
Current 1.090
EPS
Actual
Estimate
-0.25-0.19-0.12-0.06
Institutional Holdings
Institutions: 105
Institutional Holdings: 54.26M
% Owned: 77.24%
Shares Outstanding: 70.25M
TypeInstitutionsShares
Increased
16
1.49M
New
10
1.50M
Decreased
13
860.03K
Sold Out
17
2.70M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.34%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Non-Executive Chairman/Independent Director
Peter Barrett
President/Chief Executive Officer/Director
Aoife Brennan
Chief Financial Officer
Michael Jensen
Chief Operating Officer
Antoine Awad
Independent Director
Michael Burgess
Independent Director
Michael Heffernan
Independent Director
Patricia Hurter
Independent Director
Lisa Kelly-Croswell
Independent Director
Nick Leschly
Independent Director
Edward Mathers
Independent Director
Richard Shea
No Data
No Data
About SYBX
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the drug discovery and development of Synthetic Biotic medicines. Its product pipeline includes Synthetic Biotic medicines for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The Company's lead product candidate includes SYNB1618, which is an oral therapy for the treatment of PKU. Its other product candidate SYNB8802 is developed for the treatment of Enteric Hyperoxaluria. The Company developed Synthetic Biotic medicines to treat certain cancers that are designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. It is developing SYNB1891 for the treatment solid tumors and lymphoma. The Company is conducting Phase II clinical trial with SYNB1618.
Webull offers kinds of Synlogic Inc stock information, including NASDAQ:SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading SYBX stock methods without spending real money on the virtual paper trading platform.